|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Adding omeprazole to long-term amlodipine therapy in patients with hypertension and ARD may lead to a significantly more pronounced antihypertensive effect in patients genotyped CYP2C19 IMs.
|
31807051 |
2019 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Combined with a previous study on the effects of CYP2D6 variants on nebivolol metabolism, our comprehensive analyses on the enzymatic activities of CYP2C19 variants towards nebivolol in the present study may contribute to determination of the optimal doses of nebivolol for the treatment of hypertension and understanding of "individualized" medication.
|
29098786 |
2018 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among predictors associated with MACE was the carriage of one CYP2C19 loss of function allele {hazard ratio (HR) 8.6 [confidence interval (CI) 3.15-23.4]; P < 0.0005}, hypertension [HR 3.74 (CI 1.06-13.16); P = 0.04], reduced ventricular function [HR 3.88 (1.43-10.54); P = 0.008], and history of previous myocardial infarction [HR 4.9 (CI 1.48-11.33); P = 0.007] by univariate analysis, although only CYP2C19 genotype remained significant by multivariate analysis [HR 11.88 (CI 3.25-43.44); P < 0.0005].
|
29554005 |
2018 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.
|
28513222 |
2017 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Overall, nifedipine and verapamil blunts CSA hypertension but variably affected concomitantly enhanced EDHF-dependent renal vasodilations and alterations in CYP2C/CYP4A signaling.
|
28899749 |
2017 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Five hundred and three patients with an acute coronary event were studied to assess the association between the CYP2C19 activity (CYP2C19*2, CYP2C19*3 and CYP2C19*17 variants) and the type of acute coronary syndrome, cardiovascular risk factors (arterial systemic hypertension, diabetes mellitus, dyslipidemia and smoking), analytical parameters and the extent and severity of coronary atherosclerosis.
|
28473221 |
2017 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Multivariate analysis for CMVD indicated that the female sex, current smoking, and hypertension were predictive factors, and that high levels of hs-CRP and CYP2C19 PM were predictive factors in women only (odds ratio 3.5, 95% confidence interval 1.26-9.93, P = 0.033; odds ratio 4.1, 95% confidence interval 1.15-14.1, P = 0.038).
|
26993229 |
2016 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The individuals with both the CYP2C19(*)2 allele and hypertension are at high risk of CR during anti-thrombosis therapy.
|
27133299 |
2016 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Studies with rat genetic models of hypertension pointed to roles for the CYP2C and CYP4A arachidonic acid epoxygenases and ω-hydroxylases in tubular transport, hemodynamics, and blood pressure control.
|
25986599 |
2015 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The present results indicate that hypertension is associated with the AA genotype of rs10509676 in the human CYP2C19 gene.
|
21332417 |
2011 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Multiple logistic regression analysis showed 4 independent risk factors: the interaction of CYP2C19*3 and smoking (OR 7.22, 95% confidence interval [CI] 2.32-10.23; P = .009), smoking (OR 3.23, 95% CI 1.72-5.44; P = .003), blood sugar (OR 2.12, 95% CI 1.03-4.21; P < .01), and hypertension (OR 1.74, 95% CI 0.98-2.34; P = .013).
|
20460345 |
2010 |
|
Hypertensive disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Associations between genetically controlled alterations in blood pressure and the activity and/or transcriptional regulation of the kidney Cyp2c AA epoxygenases and Cyp4a omega-hydroxylases revealed a role for these enzymes in the pathophysiology of hypertension, a leading cause of cardiovascular, cerebral, and renal morbidity and mortality.
|
17597703 |
2007 |